about
Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trialsPhase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomasUtilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder.What inference for two-stage phase II trials?A Bayesian approach for unplanned sample sizes in phase II cancer clinical trialsSuspension of accrual in phase II cancer clinical trials.Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring response.VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastasesEribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemiaStatistical inference for extended or shortened phase II studies based on Simon's two-stage designsA Rescue Strategy for Handling Unevaluable Patients in Simon's Two Stage Design.Efficient confidence limits for adaptive one-arm two-stage clinical trials with binary endpoints.Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer.Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancerA review and re-interpretation of a group-sequential approach to sample size re-estimation in two-stage trials.Hypothesis testing for two-stage designs with over or under enrollment.Methods for proper handling of overrunning and underrunning in phase II designs for oncology trials.Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials.Comments on 'Hypothesis testing for two-stage designs with over or under enrollment'.Designs for randomized phase II clinical trials with two treatment arms.Estimation of secondary endpoints in two-stage phase II oncology trials.Two-stage phase II oncology designs using short-term endpoints for early stopping.Test-compatible confidence intervals for adaptive two-stage single-arm designs with binary endpoint.Exact confidence limits for the response rate in two-stage designs with over- or under-enrollment in the second stage.An Introduction to Practical Sequential Inferences via Single-Arm Binary Response Studies Using the binseqtest R Package
P2860
Q26849875-2F6EAC1C-EE97-473B-BAB6-CA345E8FC790Q33410380-FDB1EB17-F945-48A4-8BFE-C0D3F24B7B02Q33449522-4CD7D746-20B9-4BA8-A5A0-1B0E2A2E8437Q34367748-1D9DE1C3-00F3-499F-92D0-ABBD12E8687EQ34815765-FA31CBAF-3AC9-4942-801A-ADB1DE61AACEQ35164526-CD4DCE2C-91EE-4A74-94A1-A241AF4A0483Q35223807-FFA15317-2B8E-4569-9434-3B0805A6F470Q35285011-0E9EFBA8-3254-455C-86C8-A49646AF61C2Q35563368-AFCEBF2F-981E-4DDD-8044-18C595C4739BQ35633159-D3F64136-81F4-4A49-B189-4890E087FE42Q35651754-1D0BFB3E-EAE4-4B93-A614-0B171B6D418DQ35655152-87705BB3-A4CA-48F1-B50A-04BE07BA51B0Q35774468-9BA9C988-B35B-4B6A-B337-DDD19DA202EDQ36272018-EA94B4A0-E489-42CF-B41E-5B327D442012Q36366636-4C5C2899-9AA1-4807-A551-60EB10CDAEBFQ36972046-17D51E49-E24A-4B1A-86AA-02CF5E02D01EQ37235047-5A42E8CB-743A-43A4-B725-1EE8EC63D73DQ38201406-D2831917-9E39-42A2-AB0A-38F4BDCD7B9AQ41158724-F3085D76-5BED-4537-B4ED-C854AF3282B0Q41203314-4664C341-A645-438E-ADCC-A02994637607Q42141287-A9DDDAEE-0739-47D8-AA96-A4476F8B0D14Q45350479-5C7B6456-BF1D-42AF-9CE1-97CB51EFD889Q46031432-73248260-8485-4146-9B73-0FC22679FF00Q47210436-13D77D41-BBC2-4EE1-9ABD-929EA6C55ECBQ47645860-9512A83C-9E6C-478E-A670-4D62B8C3BDC0Q48117225-3F9EC60B-25AC-4666-91B3-A62E27B0D8C2Q54917644-180F5C24-D041-4018-AB6C-664B580F19CEQ56940683-2D35C9F7-1424-41A9-949B-DDA153B1BC17
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Proper inference from Simon's two-stage designs.
@en
type
label
Proper inference from Simon's two-stage designs.
@en
prefLabel
Proper inference from Simon's two-stage designs.
@en
P2860
P356
P1476
Proper inference from Simon's two-stage designs.
@en
P2093
Heidi Chen
Tatsuki Koyama
P2860
P304
P356
10.1002/SIM.3123
P407
P577
2008-07-01T00:00:00Z